ChromaDex nicotinamide riboside clinical trial results

Latest articles

Top 10 heath gadgets to live longer and healthier

Top ten health gadgets for the longevity enthusiasts in your life. As the holiday season kicks off with Thanksgiving this year, Christmas is right around...

Eliminating senescent cells in fat can alleviate signs of diabetes

Deleting dysfunctional cells could lead to game-changing treatments for diabetes and other metabolic diseases. Eliminating old, dysfunctional cells in human fat also alleviates signs of...

Longevica: bridging the gap between longevity science and consumers

Longevica CEO sheds further light on work to develop an “open research platform” to drive both longevity science and commercialisation. Following yesterday’s $2.5 million funding...

Longevity Science Summit: care of aging population talks continue

Our dive into Longevity Week's Science Summit continues... Last week, Longevity.Technology was lucky enough to attend Longevity Forum's Science Summit at Oxford's Oriel College, part...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Top 10 heath gadgets to live longer and healthier

Top ten health gadgets for the longevity enthusiasts in your life. As the holiday season kicks off with Thanksgiving this year, Christmas is right around...

Eliminating senescent cells in fat can alleviate signs of diabetes

Deleting dysfunctional cells could lead to game-changing treatments for diabetes and other metabolic diseases. Eliminating old, dysfunctional cells in human fat also alleviates signs of...

Longevica: bridging the gap between longevity science and consumers

Longevica CEO sheds further light on work to develop an “open research platform” to drive both longevity science and commercialisation. Following yesterday’s $2.5 million funding...

Click the globe for translations.

New clinical research in ataxia-telangiectasia patients finds nicotinamide riboside improved ataxia scores and increased antibody levels.

LA-based ChromaDex has shared findings from the first clinical study on nicotinamide riboside (NR) in children and highlighted improvements for prematurely aging patients with ataxia-telangiectasia (AT).

Longevity.Technology: Usually studies that impact longevity aren’t conducted in children for obvious reasons. But life-limiting conditions can affect people of all ages, and this study on the effects of NR on AT will hopefully progress research on this devastating disease. The study is interesting from an antiaging perspective as well; sufferers of AT demonstrate genomic instability, premature senescence and shortened telomeres, as well as immunodeficiency and neurodegeneration. These all correlate with aging, so if NR has promising results for AT, further research might add grist to its antiaging mill. We look forward to further findings being published in due course.

The promising findings from this clinical study were published in the peer-reviewed journal, Movement Disorders, conducted by Michèl A A P Willemsen MD, PhD of Radboud University Medical Center. The study investigated ChromaDex’s proprietary Niagen® ingredient (patented nicotinamide riboside) in patients with ataxia-telangiectasia (AT), a rare, inherited neurodegenerative disorder characterised by premature aging, cerebellar degeneration, immunodeficiency and cancer predisposition. The study found that supplementation with NR improved ataxia scores and increased immunoglobulins, or antibodies, in the immune-compromised patients.

In addition to the findings, this was the first published clinical NR trial to include participants under the age of 18, examining the potential impact NR might have in children with AT.

“AT is a condition where children experience the negative effects of premature aging with a very limited life expectancy,” said Dr Andrew Shao, ChromaDex Senior Vice President of Global Scientific & Regulatory Affairs. “The results of this study are promising for those living with AT and are consistent with previous preclinical research. We look forward to the continued clinical research exploring the impact of Niagen on age-related health declines [1].”

This study included 24 AT patients (15 males, 9 females), and 17 of the 24 were children under 18. The patients’ average age was 17.5 and no one in the study had previously supplemented with NR. The group received 25mg/kg body weight of NR per day for four consecutive months, followed by a two-month period without NR treatment. The effects of NR on ataxia (a group of disorders that affect coordination, balance and speech), dysarthria (a motor speech disorder), quality of life and laboratory parameters were analysed.

NR improved ataxia scores in patients and increased serum immunoglobulin G (IgG), or antibodies, which are important for protection against pathogens. Patients with AT are known to be immunodeficient with decreased serum immunoglobulins concentrations [2].

These results suggest that NAD+ boosting may be a potential therapeutic strategy for AT, however, further research needs to be conducted.

[1] https://investors.chromadex.com/news/news-details/2021/ChromaDex-Shares-Findings-from-First-Clinical-Study-on-Nicotinamide-Riboside-NR-in-Children-Highlighting-Improvements-for-Prematurely-Aging-Patients-with-Ataxia-Telangiectasia-AT/default.aspx
[2] https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.28788

Subscribe for $1 and get full access to the Supplements Report Subscribe

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Longevica: bridging the gap between longevity science and consumers

Longevica CEO sheds further light on work to develop an “open research platform” to drive both longevity science and commercialisation. Following yesterday’s $2.5 million funding...

A diet of essential amino acids could delay dementia

Consuming Amino LP7, a specific combination of essential amino acids, could delay the development of dementia, shows a study from Japan​. The intake of protein,...

Everything you ever needed to know about cell stress

MitoQ's William Stow on cell stress – what it is and what we can do about it. William Stow is the Chief Scientific Officer at...

Mediterranean research institute spawns longevity companies

Fundamental research at MedILS has already led to the creation of longevity companies working on skin rejuvenation, antiaging supplements and biotech. The Mediterranean Institute for...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

    Subscribe to our newsletter